Structure Obesity Pill Results Rival Novo, Lilly Treatments

Structure Therapeutics Inc.’s shares rose after more data on the company’s experimental weight-loss pill showed it’s shaping up to rival new oral treatments from Novo Nordisk A/S and Eli Lilly & Co.

Patients on Structure’s once-daily pill, called aleniglipron, lost about 15% of their body weight after 44 weeks, while those given a placebo added a few pounds, the company said on Monday. There was no weight-loss plateau, and nausea and vomiting were the most common side effects.